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RhoB controls coordination of adult angiogenesis
and lymphangiogenesis following injury by
regulating VEZF1-mediated transcription
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Mechanisms governing the distinct temporal dynamics that characterize post-natal angio-
genesis and lymphangiogenesis elicited by cutaneous wounds and inﬂammation remain
unclear. RhoB, a stress-induced small GTPase, modulates cellular responses to growth
factors, genotoxic stress and neoplastic transformation. Here we show, using RhoB null mice,
that loss of RhoB decreases pathological angiogenesis in the ischaemic retina and reduces
angiogenesis in response to cutaneous wounding, but enhances lymphangiogenesis following
both dermal wounding and inﬂammatory challenge. We link these unique and opposing roles
of RhoB in blood versus lymphatic vasculatures to the RhoB-mediated differential regulation
of sprouting and proliferation in primary human blood versus lymphatic endothelial cells. We
demonstrate that nuclear RhoB-GTP controls expression of distinct gene sets in each
endothelial lineage by regulating VEZF1-mediated transcription. Finally, we identify a small-
molecule inhibitor of VEZF1–DNA interaction that recapitulates RhoB loss in ischaemic
retinopathy. Our ﬁndings establish the ﬁrst intra-endothelial molecular pathway governing the
phased response of angiogenesis and lymphangiogenesis following injury.
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L
arge organisms exhibit two different vascular networks
essential for life. The circulatory blood vascular network,
arising during embryonic development by both vasculo-
genesis and angiogenesis, provides oxygen, nutrients, hormones
and cells to tissues, and collects carbon dioxide and other
metabolic waste products1. The blind-ended lymphatic vascular
network that subsequently originates from the embryonic
cardinal vein by budding and differentiation of a subpopulation
of blood vascular endothelial cells (BVECs) regulates tissue ﬂuid
homoeostasis, immune cell trafﬁcking and absorption of dietary
fats2. Similarly in adults, studies have shown that angiogenesis
precedes lymphangiogenesis during the repair of damaged
tissues3–9. However, the underlying mechanisms that timely
coordinate these processes are still elusive. Considering the close
identity between blood and lymphatic endothelial cells, a central
question still unresolved is how blood vessels quickly engage in
the revascularization of damaged tissues, while the growth of
lymphatics is delayed in response to the same pathological
stimulus.
RhoB is an immediate early response gene rapidly inducible by
many stimuli including genotoxic stress, cytokines and growth
factors10–13. In contrast to related members of the RhoA/Rac1/
Cdc42 family of small GTPases, RhoB is primarily localized on
endosomes and in the nucleus, and has been shown to regulate
vesicle and growth factor receptor trafﬁcking14–18. RhoB null
mice are viable, indicating that RhoB is dispensable for normal
development19; however, RhoB can alter tumour formation by
limiting tumour cell growth but yet promoting tumour
angiogenesis20,21. Studies in RhoB null mice indicate that RhoB
is a critical modiﬁer of apoptosis triggered by genotoxic stress.
RhoB promotes apoptosis in response to DNA damage in
transformed ﬁbroblasts19, but protects transformed keratinocytes
from UVB-induced apoptosis, suggesting that RhoB’s functions
are both stress- and context-dependent13. Our previous studies
revealed the contribution of this small GTPase to the blood
vasculature in the developing retina, that is, defective endothelial
tip cell sprouting occurred in RhoB null mice18. We found that
RhoB is a determinant of Akt stability and trafﬁcking to the
nucleus, and that this function has a stage-speciﬁc role in the
survival of sprouting BVECs that contribute to new blood vessel
assembly during post-natal retinal development.
Given its critical roles in both the stress response and vascular
morphogenesis, we hypothesized that RhoB might also be
relevant in adult pathological scenarios involving endothelial cell
challenge, such as wound healing, inﬂammation or reperfusion
injury. Herein we examine the effect of RhoB deletion on
pathological angiogenesis associated with ischaemic retinopathy,
as well as on angiogenesis and lymphangiogenesis elicited by
dermal injury or inﬂammation. Using primary human BVECs
versus lymphatic vascular endothelial cells (LVECs), we investi-
gate the role that RhoB serves in regulating proliferation and
sprouting in these two endothelial populations. We explore the
possibility that RhoB is functionally linked to the zinc ﬁnger
transcription factor DB1/VEZF1, a molecule known to regulate
embryonic angiogenesis and lymphangiogenesis22, and previously
reported to be a RhoB-interacting protein in vitro14. We perform
transcriptome analyses to uncover unique sets of relevant genes
targeted by VEZF1 and co-regulated by RhoB in BVECS versus
LVECs, leading us to postulate a novel mechanism responsible for
the temporally coordinated response of the blood and lymphatic
networks to injury.
Results
RhoB loss normalizes blood vasculature in OIR. We employed
the mouse model of oxygen-induced retinopathy (OIR)23 in
neonatal wild-type (wt) and RhoB / mice to evaluate the
effect of RhoB loss in a pathological angiogenic environment.
After 5 days at 70% oxygen (P7–P12), the retinal vasculature in
both wt and RhoB / pups exhibited profound vessel
regression, particularly in the central portion near the optic
disc (OD), conﬁrming that the initial vascular response to high
oxygen is not altered in the absence of RhoB (Fig. 1a,
Supplementary Fig. S1). Subsequently, after 5 days of room
air (P12–P17), wt pups mounted a robust pathological
neovascularization typiﬁed by abnormalities in vascular
structure, that is, formation of glomeruloid bodies or ‘vascular
tufts’ (arrowheads), large avascular areas (star) and endothelial
cell invasion through the inner limiting membrane (ILM) into
the vitreous (arrows). In contrast, RhoB / mice showed a
dramatic reduction in glomeruloid bodies and 100-fold reduced
intra-vitreous invasion rate. RhoB loss during ischaemic
retinal neovascularization converts the resultant pathological
neovascular network to a more physiological phenotype.
Angiogenesis and lymphangiogenesis in RhoB / wounds. To
evaluate the impact of RhoB deletion in another tissue, we sub-
jected the mouse ear to a full-thickness wound. New blood vessels
appeared in the granulation tissue of wt mice by day 7 after
wounding (Fig. 1b), whereas after 1 week RhoB / mice
exhibited poor neovascularization with a twofold decreased vas-
cular density. Interestingly in RhoB / mice, CD31 immuno-
staining revealed not only the presence of positively stained blood
vessels, but additional structures with a different morphology and
weak staining intensity (arrowheads). CD31 is also known to be
expressed by lymphatic endothelial cells24. To validate the
lymphatic identity of these additional vascular structures, we
stained for podoplanin, a protein that is speciﬁcally expressed in
the lymphatic endothelium (Fig. 1c). Colocalization of CD31 and
podoplanin conﬁrmed numerous lymphatic vessels inﬁltrating
and surrounding the granulation tissue speciﬁcally in RhoB /
mice (arrowheads).
In agreement with previous studies6,9,25, injection of
macromolecular FITC–dextran tracer into the dermal lymphatic
vessels in wt mice on day 7 post-wounding revealed no obvious
new lymphatics associated with the granulation tissue (Fig. 2a and
Supplementary Movie 1). In contrast, RhoB / mice exhibited a
profound lymphangiogenic response as judged by the rapid ﬁlling
of a distinct lymphatic network beginning between 2–10 s after
tracer injection and progressively increasing by 30 s
(Supplementary Movie 2), indicating more numerous lymphatic
vessels (twofold increase) and an elevated interconnectivity in the
lymphatic network adjacent to the wound. Thereafter, between 30
and 60 s, FITC–dextran accumulated in the tissue immediately
surrounding the ﬁlled lymphatics (arrowheads), far from the
tracer injection site, suggesting an abnormal structure of these
new lymphatics leading to the enhanced leakage of ﬂuid and
macromolecules. Confocal analysis following whole-mount
staining with anti-podoplanin conﬁrmed lymphatic lumen
enlargement and impaired lymphatic barrier integrity in the
RhoB / granulation tissue (respectively, arrowhead and
star, Fig. 2b).
RhoB loss enhances lymphangiogenesis in chronic inﬂammation.
Using oxazolone as a sensitizing agent26, we induced a delayed-
type hypersensitivity (DTH) reaction and assessed the level
of oedema accompanying this model of chronic inﬂammation
by measurement of ear thickness (Fig. 2c). The maximum extent
of oedema, reached by day 2 after oxazolone application, was
signiﬁcantly higher in RhoB / ears as compared to wt.
Thereafter, ear swelling declined more slowly and remained
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signiﬁcantly higher in RhoB / compared with wtmice even after
11 days, indicating that resolution of ﬂuids that accumulated during
the inﬂammatory phase is impaired in the RhoB / mice.
Visualization of the lymphatic network at 7 days post challenge by
intralymphatic injection of FITC–dextran tracer revealed a massive
lymphangiogenic response in RhoB / mice characterized by
more numerous lymphatic vessels, enhanced lymphatic
interconnectivity and dramatic FITC–dextran leakage into the
surrounding tissue (Fig. 2d, Supplementary Movie 4) as compared
with wt (Supplementary Movie 3).
RhoB differentially affects BVEC and LVEC response to stress.
Using pure populations of human primary BVECs and LVECs
isolated from foreskin (Supplementary Fig. S2), we determined
the relative amounts of RhoB protein found in BVECs versus
LVECs during resting conditions (cells at 100% conﬂuence for
48 h without media renewal), or during proliferative conditions
(cells collected 24 h and 48 h after challenge initiated by trypsi-
nization of conﬂuent cultures followed by re-plating at 50%
density) (Fig. 3a). RhoB was constitutively expressed in both
resting and proliferating BVECs, but was barely detectable in
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Figure 1 | RhoB loss normalizes angiogenesis in OIR and decreases BV density in granulation tissue. (a) Whole-mount staining of blood vessels
(BS-I lectin) in the retina of wt and RhoB / pups subjected to hyperoxia from P7 to P12, and then returned back to normoxia from P12 to P17 (OD, optic
disc). Histological (H&E) analysis of wt and RhoB / retinas at P17. Quantiﬁcation of nuclei number interior to ILM (n¼ 10 mice per genotype,
mean±s.e.m., unpaired two-tailed Student’s t-test). (b) Confocal analysis following whole-mount staining of CD31 expression in the granulation tissue
present 7 days after ear wounding in adult wt and RhoB / mice (6–8 weeks old). Quantiﬁcation of CD31-positive staining in the neovasculature of the
granulation tissue (delineated with white lines) (n¼6 mice per genotype, mean±s.e.m., unpaired two-tailed Student’s t-test). (c) Confocal analysis
following whole-mount staining of CD31 and podoplanin expression in the granulation tissue present 7 days after wounding. Arrowheads highlight
lymphatic vessels and denote areas of colocalization of CD31 and podoplanin in the merged image, thus conﬁrming the identity of the lymphatic vessels.
Scale bars: whole-mount staining¼ 100mm, H&E sections¼ 50mm (a), 200mm (b,c).
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LVECs at rest and at 48 h after challenge. Interestingly, the level
of RhoB protein increased in both BVECs and LVECs 24 h after
proliferative challenge, suggesting that RhoB has a critical role in
the immediate response of both BVECs and LVECs to stress.
Next, we either silenced or overexpressed RhoB, by siRNA
nucleofection or adenovirus infection, respectively, and subjected
conﬂuent cultures of the modiﬁed cells to proliferative stress
(Fig. 3b). Immunostaining of pre-conﬂuent cells 24 h following
proliferative stress for the proliferation marker Ki67 showed that
RhoB silencing decreased the percent of proliferating BVECs
twofold, but nearly doubled the percent of proliferating of LVECs
(Fig. 3c). In direct contrast, RhoB overexpression signiﬁcantly
promoted the proliferation of BVECs, but repressed LVECs
proliferation. Finally, using a three-dimensional (3D) sprouting
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Figure 2 | RhoB loss leads to enhanced and abnormal lymphangiogenesis in response to stress. (a) Intravital microlymphangiography by in vivo
injection of FITC–dextran (MW 2,000kDa) into lymphatics of ear skin 7 days after ear wounding in adult wt and RhoB / mice. Dextran-positive areas in
isolated frames taken from the movies at early (2–10 s (s)), middle (30 s) and late (60 s) times following tracer injection were quantiﬁed (n¼ 7 mice per
genotype, mean±s.e.m., unpaired two-tailed Student’s t-test). (b) Confocal analysis following in vivo FITC–dextran injection in lymphatics and whole-
mount staining of podoplanin expression in the granulation tissue present 7 days after ear wounding in adult wt and RhoB / mice. Arrowhead and star
respectively highlight dextran leakage from an abnormal lymphatic vessel and tracer accumulation in the adjacent tissue of RhoB / mice in the merged
image. (c) Induction of DTH reactions in the ear skin of adult wt and RhoB / mice. Ear swelling is expressed as the increase (D) over the original ear
thickness in mm. Ear thickness was measured daily for 11 days following challenge using a Mitutoyo caliper (n¼ 12 mice per genotype, mean±s.e.m.,
unpaired two-tailed Student’s t-test). (d) Intravital microlymphangiography by in vivo injection of FITC–dextran (MW 2,000 kDa) into lymphatics of
ear skin 7 days after inﬂammation induced by oxazolone in adult wt and RhoB / mice. FITC–dextran-positive areas in isolated frames taken from movies
at early (2–10 s (s)), middle (30 s) and late (60 s) times following tracer injection were quantiﬁed (n¼6 mice per genotype, mean±s.e.m., unpaired
two-tailed Student’s t-test). Scale bars: 1mm (a,d) and 100 mm (b).
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assay, we observed that RhoB silencing reduced the sprouting of
BVECs induced by VEGF-A and led to increased sprouting of
LVECs stimulated by VEGF-C (Fig. 3d). In contrast, RhoB
overexpression had the reverse effect, that is, a higher number of
BVECs sprouted in response to VEGF-A, and a lower number of
LVECs sprouted in response to VEGF-C (Fig. 3d). These results
demonstrate that RhoB serves cell-autonomous, yet opposing,
roles in two essential features of blood and lymphatic endothelial
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Figure 3 | Differential regulation of proliferation and sprouting in BVECs and LVECs by RhoB. (a) Representative western blot showing the
endogenous level of RhoB protein in BVECs and LVECs in the resting state (100% conﬂuence for 48 h without media renewal) versus the proliferative state
(24 h and 48 h after challenge initiated by cell plating at low, that is, 50%, density). Western blotting for a related GTPase, RhoA, did not indicate any
variation in RhoA expression levels in BVECs or LVECs under resting or proliferative conditions and thus conﬁrmed the speciﬁcity of the RhoB antibody
and the unique regulation of RhoB in these cells. Tubulin was used as loading control. (b) Representative western blot showing the efﬁciency of RhoB
silencing by siRNA nucleofection, and the level of RhoB overexpression following adenovirus infection, in BVECs and LVECs 24 h after proliferative
challenge. The RhoB-Flag protein was detected using antibodies directed against the RhoB protein and by antibodies against the Flag tag. (c) Proliferation
index of BVECs and LVECs after RhoB silencing and RhoB overexpression at 24 h after proliferative challenge, determined as the ratio of the number
of Ki67 positive cells to the total number of cells (expressed as %, nZ600 total cells taken from at least six ﬁelds with at least 100 cells per ﬁeld per condition,
mean±s.e.m., unpaired two-tailed Student’s t-test). (d) Sprouting from BVECs and LVECs spheroids in 3D Matrigel–collagen I matrix, induced for 24h by
VEGF-A or VEGF-C, respectively, after RhoB silencing (phase-contrast pictures) or RhoB overexpression (ﬂuorescent confocal projections). GFP expression,
resulting from infection with the RhoB adenoviral vector containing an IRES-GFP, was used as an internal control for the overexpression experiments. Individual
sprouts in RhoB-silenced cells are noted by red (BVECs) or green (LVECs) arrowheads, and in RhoB-overexpressing cells by white arrowheads. Quantitative
analysis of endothelial cell sprouting was performed by measuring the cumulative length of all of the sprouts originating from one spheroid (described
previously47), using NIH ImageJ software (n¼ 10 spheroids, mean±s.e.m., unpaired two-tailed Student’s t-test). Scale bars: 50mm (d).
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cell biology, that is, proliferation and sprouting. Overall these
in vitro results equate directly with our in vivo observations: (1) in
the OIR model, the dramatic reduction in the number of glo-
meruloid bodies, which are formed as a consequence of BVEC
hyper-proliferation in the retina and (2) in the dermal wound
healing and DTH models, the enlarged, highly interconnected
and leaky lymphatic vessels, which were previously shown to be
correlated with LVEC proliferation and the unstable sprouting tip
cell phenotype27–29.
RhoB collaborates with VEZF1. To decipher the molecular
mechanisms responsible for the differential effect of RhoB in
blood and lymphatic vascular beds, we investigated the possibility
that RhoB is functionally linked to the zinc ﬁnger transcription
factor VEZF1. VEZF1 is known to regulate embryonic angio-
genesis and lymphangiogenesis22, and has previously been
reported to be a RhoB-interacting protein in vitro14. As
VEZF1 / mice are embryonic lethal, we crossed mice from
the RhoB and VEZF1 heterozygotes and generated an allelic series
of mice, that is, RhoBþ / , VEZF1þ / and RhoBþ /VEZF1þ / .
Using the OIR assay, we observed that loss of only one RhoB
allele did not alter the pathological angiogenic response in the
retina of RhoBþ / mice as compared with wt (Fig. 4a). However,
VEZF1þ / mice exhibited a reduced pathological angiogenic
response (twofold decrease in the number of nuclei interior to
ILM) (Fig. 4a), which is further reprogrammed to more
physiological angiogenesis in RhoBþ /VEZF1þ / mice,
similarly to RhoB / mice (Fig. 4a). In parallel, we assessed
the lymphangiogenic response to challenge using the ear wound
model. By day 7 post wounding, in dramatic contrast to what we
observed in the RhoB / mice (Fig. 2a), injection of FITC–
dextran tracer did not reveal new lymphatics in the region
immediately surrounding the site of the wound in RhoBþ /
mice (Fig. 4b and Supplementary Movie 5). In contrast, in
RhoBþ /VEZF1þ / mice, the lymphangiogenic response was
comparable to that observed in the RhoB / mice (Fig. 4b and
Supplementary Movie 7). Interestingly, VEZF1þ / mice exhibit
an intermediate lymphatic phenotype with the emergence of
several leaky lymphatics around the granulation tissue
(arrowhead, Fig. 4b, Supplementary Movie 6).
To address the interaction of RhoB with VEZF1 at the
molecular level, we investigated the subcellular localization of
these two proteins in BVECs and LVECs. Although RhoB was
detected predominantly in the cytoplasm of both BVECs and
LVECs, in both cell types this small GTPase was also located in
the nucleus, where VEZF1 protein was exclusively detected
(Fig. 4c). Moreover, using a proximity ligation assay we were able
to demonstrate a protein complex containing V5-tagged RhoB
and Flag-tagged VEZF1 located in the nucleus of both BVECs and
LVECs (Fig. 4d, arrowheads). Taken together, these studies
strongly argue that RhoB genetically interacts with VEZF1 in the
regulation of the altered blood vascular response to ischaemia as
well as in the temporal repression of lymphangiogenesis during
wound healing, and indicate that RhoB belongs to a nuclear
transcriptional complex containing VEZF1.
RhoB and VEZF1 share target genes in BVECs and LVECs. To
uncover how the collaboration between RhoB and VEZF1 affects
BVEC and LVEC biology, we performed Affymetrix microarray
analyses after silencing either RhoB or VEZF1 in both endothelial
cell types (Supplementary Fig. S3). A signiﬁcant number of the
deregulated probe sets in RhoB-silenced BVECs matched the
deregulated probe sets in VEZF1-silenced BVECs (214 down-
regulated and 243 upregulated probe sets). Similarly, 1,413
downregulated probe and 1,280 upregulated probe sets in RhoB-
silenced LVECs compared favourably to the deregulated probe sets
in VEZF1-silenced LVECs, suggesting that these deregulated probe
sets could correspond to the speciﬁc genes targeted by VEZF1 and
co-regulated by RhoB. Using gene ontology (GO) classiﬁcation to
query the function of the target genes shared by RhoB and VEZF1,
we identiﬁed ontology categories important for different aspects of
endothelial cell biology including proliferation and sprouting
(Supplementary Table S1). Among the subsets of shared target
genes (Supplementary data 1), we conﬁrmed the role of RhoB and
VEZF1 in the regulation of expression of a ﬁnite number of par-
ticularly relevant genes by QRT–PCR (Fig. 5a, Supplementary
Fig. S4a). For example, the VEGF-A receptor, VEGF-R2, and its
co-receptor, Neuropilin1 (NRP1), were both downregulated in
BVECs after silencing of either RhoB or VEZF1 (twofold decrease
in silenced cells compared with control). Although these two genes
were also detected in the LVECs microarrays, QRT–PCRs revealed
a lower basal level of expression and an insigniﬁcant decrease after
silencing of either RhoB or VEZF1 in these cells, suggesting a
predominant effect of RhoB-VEZF1 on VEGF-R2 and NRP1
expression in BVECs compared with that in LVECs. By contrast,
the metallopeptidase inhibitor, TIMP3, was more highly expressed
in LVECs, suggesting that downregulation of this protein, triggered
by both RhoB and VEZF1 knockdown, has a particularly potent
impact in LVECs versus BVECs.
To identify the direct target genes of VEZF1, and more
importantly, those that are also co-regulated by RhoB, we
analysed the binding of these two proteins to a number of
selected promoters by chromatin immunoprecipitation (ChIP).
Initially, we conﬁrmed chromatin enrichment of the endothelin1
promoter, known to be a direct target of VEZF1 (ref. 30), in
BVECS after VEZF1 immunoprecipitation, thus validating our
ChIP protocol (Supplementary Fig. S4b). Interestingly, we also
discovered sequences containing potential VEZF1 DNA binding
sites in the promoter regions of VEGF-R2 and NRP1 (Fig. 5b).
These regions exhibit three- and twofold enrichment, respec-
tively, after VEZF1 or RhoB-Flag immunoprecipitation, speciﬁ-
cally in BVECs. In contrast, the chromatin of the TIMP3
promoter regions, which also contains putative VEZF1 DNA
binding sites, is enriched fourfold after VEZF1 or RhoB-Flag
immunoprecipitation, speciﬁcally in LVECs (Fig. 5b). Taken
together, these data suggest that RhoB works in conjunction with
VEZF1 on speciﬁc promoters to regulate the expression of
essential direct target genes involved in the proliferation and
sprouting of endothelial cells. Of critical importance, these sets of
direct targets appear to be different in BVECs versus LVECs.
RhoB-GTP speciﬁcally controls BVEC and LVEC proliferation.
A signiﬁcant feature of many small GTPases is their ability to
toggle intrinsic GTPase activity between ‘on’ and ‘off’ states, as
determined by the ratio of the GTP-bound to the GDP-bound
forms of the enzyme31. To assess the importance of these two
states in the regulatory function of RhoB in endothelial cells, we
prepared adenoviral vectors encoding mutants of RhoB and used
them to elicit overexpression of three different forms of the RhoB
GTPase: wt (adRhoB), the RhoB dominant negative form
corresponding to the GDP-bound state (adRhoB-DN) and the
RhoB constitutively active form corresponding to the GTP-bound
state (adRhoB-CA). Overexpression of wt or mutant RhoB was
performed in BVECs and LVECs undergoing proliferative
challenge and the corresponding GTP levels were measured by
GTP pull-down assay (Fig. 6a). Neither BVECs nor LVECs
infected with adRhoB-DN exhibited any detectable amount of
GTP-bound RhoB, whereas both cell types infected with adRhoB-
CA showed high levels of expression of the GTP-bound form of
RhoB. Following wt RhoB overexpression, a substantial amount
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Figure 4 | Functional interaction between RhoB and VEZF1 during OIR and wound healing. (a) Whole-mount staining of blood vessels (BS-I lectin)
in the retina of RhoBþ / , VEZF1þ / and RhoBþ /VEZF1þ / pups (P17) subjected to OIR assay (OD¼Optic Disc). Histological (H&E) analysis of
RhoBþ / , VEZF1þ / and RhoBþ /VEZF1þ / retinas at P17. Quantiﬁcation of the number of nuclei interior to ILM (n¼ 6 per genotype, mean±s.e.m.,
unpaired two-tailed Student’s t-test). (b) Intravital microlymphangiography by in vivo injection of FITC–dextran (MW 2,000kDa) into lymphatics of
ear skin 7 days after ear wounding in adult RhoBþ / , VEZF1þ / and RhoBþ /VEZF1þ / mice, shown at 60 s post tracer injection. Dextran-positive
areas in isolated frames taken from the movies at early (2–10 s (s)), middle (30 s) and late (60 s) times following tracer injection were quantiﬁed (n¼6
mice per genotype, mean±s.e.m., unpaired two-tailed Student’s t-test). (c) Representative western blot of nuclear and cytoplasmic extracts showing
the dual localization of RhoB in both nuclei and cytoplasm of BVECs and LVECs, whereas another RhoGTPase, RhoA, was detected only in the cytoplasm. In
contrast, VEZF1 was exclusively detected in nuclei. DNA Polb and Tubulin proteins were used as internal controls for nuclear and cytoplasmic extracts,
respectively. (d) Confocal analysis of in situ proximity ligation assay (PLA) (red) using anti-V5 and anti-Flag allows visualization of the interaction
of RhoB-V5 and VEZF1-Flag in the nucleus (DAPI—blue) of both transfected BVECs and LVECs (right panels—arrowheads) versus control untransfected
cells (left panels), which exhibit only non-speciﬁc background staining in the cytoplasm. Scale bars: whole-mount staining¼ 100mm, H&E sections¼ 50mm
(a), 1mm (b) and 10mm (d).
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of RhoB in the GTP-bound state could be detected in both BVECs
and LVECs, indicating that both cell types maintain RhoB in a
predominantly active form under proliferating conditions. To
evaluate the possibility that the state of RhoB determines its
localization within the cell, we analysed the subcellular pattern of
these RhoB mutants (Fig. 6b). wt RhoB and all mutants of RhoB,
including the dominant negative RhoB, were detected in the
cytoplasm as well as in the nucleus of BVECs and LVECs,
indicating that both the GTP- and the GDP-bound states of RhoB
can be found within the nucleus.
To determine the biological effect of the GTP-bound versus the
GDP-bound form of RhoB, we measured the proliferative index
of BVECs and LVECs overexpressing either wt or mutant RhoB
(Fig. 6c). As previously observed, wt RhoB promotes and
represses the proliferation of BVECs versus LVECs, respectively.
Interestingly, whereas RhoB-DN did not affect the proliferation
rate of either type of endothelial cell, RhoB-CA inﬂuenced the
proliferation of BVECs and LVECs similarly to wt RhoB. The lack
of effect on proliferation by the RhoB-DN correlates with its
inability to regulate genes previously identiﬁed as RhoB-VEZF1
targets such as VEGF-R2, NRP1 and TIMP3 (Fig. 6d). Altogether,
these results suggest that both forms of RhoB may exist as part of
the nuclear RhoB–VEZF1 transcriptional complex. However, only
RhoB-GTP has the ability to regulate the expression of genes that
are speciﬁc targets of RhoB–VEZF1 and modulate the prolifera-
tion rate of BVECs and LVECs.
Targeting VEZF1 normalizes pathological angiogenesis in
OIR. Findings presented in Figs 1a and 4a suggest that RhoB in
collaboration with VEZF1 promotes pathological angiogenesis
accompanying OIR. We hypothesized that by interfering with the
RhoB–VEZF1 pathway we might restore physiological revascu-
larization in this setting. To target the RhoB–VEZF1–DNA
complex we focused on the DNA-binding domain of VEZF1
composed of a zinc ﬁnger domain designed to recognize a speciﬁc
DNA promoter sequence32. C2H2 zinc ﬁngers occur in tandem
arrays with many transcription factors composed of three or
more ﬁngers working in concert to bind its appropriate
promoter33,34. Using an in silico approach we identiﬁed a small
molecule that could inhibit the interaction of VEZF1 with DNA
(D.S.; personal communication). This structurally unique drug-
like small molecule inhibitor of VEZF1 (VEC6; NSC 11435; two-
dimensonal (2D) structure in Supplementary Fig. S5) signiﬁcantly
repressed NRP1 promoter-dependent luciferase activity in the
presence of RhoB and VEZF1 overexpression (Fig. 7a). To further
validate the efﬁcacy of this compound, the expression pattern of
several target genes downstream of RhoB and VEZF1 was
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Figure 5 | Target genes shared by RhoB and VEZF1 in BVECs and LVECs. (a) Relative mRNA levels of VEGF-R2, NRP1 and TIMP3 in BVECs and
LVECs following silencing of either RhoB or VEZF1 as determined by QRT–PCR (performed in triplicate on two different cell isolation lots, mean±s.e.m.,
unpaired two-tailed Student’s t-test). (b) In vivo binding of VEZF1 and RhoB-Flag to the promoter region of target genes, that is, VEGF-R2, NRP1 and
TIMP3, containing predicted in silico VEZF1 DNA binding sites (red triangle in schematic drawing of promoters) assessed by ChIP experiments. The start
site of transcription is referred as þ 1. The position of primers used for QRT–PCR experiments is represented by blue arrows. The enrichment for each
DNA fragment upon immunoprecipitation of VEZF1 and RhoB-Flag is illustrated as histograms based on % of input (QRT–PCR performed in triplicate
on two different cell isolation lots, mean±s.e.m., unpaired two-tailed Student’s t-test).
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evaluated in BVECs and LVECs undergoing proliferative stress in
the absence or presence of VEC6 (Fig. 7b). This inhibitor
repressed the expression of VEGF-R2, NRP1 and TIMP3 as
determined by QRT–PCR. Interestingly, VEC6 phenocopies the
opposing effects of RhoB-VEZF1, that is, it represses the
proliferation of BVECs, and promotes the proliferation of
LVECs (Fig. 7c). Importantly, these data provide additional
support that VEC6 is working ‘on target’ to effectively modulate
the RhoB–VEZF1–DNA complex. To evaluate the efﬁcacy of this
compound in vivo, neonatal RhoBþ / mice were subjected to
the OIR assay in the presence of VEC6 or DMSO (vehicle),
administered during the pathological phase (P12–P17) (Fig. 7d).
Pups treated with DMSO showed no change in their pathological
angiogenic response (compare Fig. 7d). However, VEC6
treatment increased the emergence of blood vessels with a
normal morphology (arrowheads), and reduced both the
avascular areas and pathological glomeruloid bodies (more than
twofold decrease in the number of nuclei interior to ILM). These
data indicate that the VEZF1 inhibitor, VEC6, can modulate the
activity of the RhoB–VEZF1 complex by disrupting the VEZF1–
DNA interaction interface similar to the loss of RhoB.
Discussion
Loss of RhoB decreased the extent of pathological angiogenesis in
the ischaemic retina and led to a reduction in angiogenesis
in response to dermal wounding, but unexpectedly enhanced
lymphangiogenesis following both dermal wounding and inﬂam-
matory challenge. Although RhoB is induced in both BVECs and
LVECs subjected to proliferative stress, RhoB promotes prolifera-
tion and sprouting in BVECs, but represses these functions in
LVECs. We investigated the importance of a direct interaction
between RhoB and the transcription factor VEZF1 in both BVECs
and LVECs, and demonstrated that the GTP-bound form of RhoB
found in the nucleus exclusively regulates VEZF1-mediated
transcription of unique and relevant target genes in BVECs versus
LVECs. We propose that this differential regulation is responsible,
at least in part, for the well-documented phenomenon of delayed
lymphangiogenesis observed in pathological settings in vivo3,4,25.
VEZF1 encodes a zinc ﬁnger transcription factor essential for
developmental angiogenesis and lymphangiogenesis. VEZF1 /
embryos exhibit vascular remodelling defects, loss of vascular
integrity, internal bleeding and embryonic death. Haploinsufﬁ-
ciency is observed in 20% of VEZF1þ / embryos, resulting in
lymphatic hypervascularity, oedema and haemorrhage22. Our
present work provides further evidence for the cooperation of
RhoB and VEZF1, particularly in the adult. To our knowledge,
this is the ﬁrst demonstration of a protein complex, that is, RhoB–
VEZF1, which serves intra-cellular and opposing regulatory roles
in two closely related endothelial cell types (Fig. 8a).
In particular, our work highlights the importance of the RhoB–
VEZF1 pathway in the temporal regulation of angiogenesis and
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(c) Proliferation index of BVECs and LVECs after overexpression of wt RhoB-Flag and its mutants at 24 h after proliferation challenge, determined as the
ratio of the number of Ki67 positive cells to the total number of cells (expressed as %, nZ600 total cells taken from at least six ﬁelds with at least
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lymphangiogenesis during wound healing. Tissue damage (for
example, skin wounds) triggers a healing response precisely
coordinated through different phases, that is, haemostasis/
inﬂammation, proliferation and remodelling/repair (Fig. 8b).
The early pro-angiogenic response participates in the initial
inﬂammatory phase by facilitating recruitment of inﬂammatory
cells into the wound bed (Supplementary Movie 8). Thereafter,
the formation of local oedema enhances the migration of
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inﬂammatory cells, endothelial cells and myoﬁbroblasts through
the loose ﬁbrin-rich provisional matrix of the granulation tissue
to begin wound repair. Subsequently, the formation of new
lymphatics aids in the drainage of excess ﬂuid, cells and debris, to
allow the remodelling phase to proceed, ultimately resulting in
wound closure. Thus, RhoB, by its interaction with VEZF1,
actively participates in ensuring the delay in lymphangiogenesis
that appears to be crucial to the success of the overall wound-
healing programme.
Among the direct target genes of RhoB–VEZF1 pathway that
we identiﬁed in BVECs, both VEGF-R2 and NRP1 are known to
support angiogenesis elicited by the pro-angiogenic cytokine
VEGF-A. The downregulation of these two receptors in the
absence of RhoB would be expected to impair angiogenesis in
response to pathological challenge, in agreement with our in vivo
observations of decreased angiogenesis in two different tissues.
Another gene that is downregulated in BVECS after silencing
either RhoB or VEZF1 is the prolyl hydroxylase domain-2 protein,
PHD2. PHD2 has been shown to be involved in normalization of
tumour vascular network35. Haplodeﬁciency of PHD2 also
redirects the speciﬁcation of endothelial tip cells to a more
quiescent cell type, lacking ﬁlopodia35 and this could contribute
to the normalization of the pathological vascular phenotype that
we observed it the OIR model. Of the set of speciﬁc target genes
that we identiﬁed in LVECs, MMP2 has already been linked with
lymphatic sprouting36, but two other genes, that is, TIMP3 and
Vasohibin1, have not historically been implicated in LVEC
biology. However, recent data implicate Vasohibin1 in the
inhibition of lymphangiogenesis and metastasis, supporting a
potential correlation with the abnormal lymphatic phenotype
(vessel enlargement and leakage) observed in our mice37. Thus,
our study provides important new information to the growing list
of genes speciﬁc to the blood versus lymphatic vasculature.
Although we were unable to evaluate the impact of the RhoB–
VEZF1 pathway on wound closure in the ear model, our parallel
study of dorsal skin excisional wound healing revealed that
healthy RhoB / mice did not exhibit any signiﬁcant difference
in the time required for complete wound closure as compared
with wt mice38. This result correlates with previous work, that is,
earlier and increased lymphangiogenesis elicited by VEGF-A
overexpression did not affect the time required for wound closure
in healthy animals6. In contrast, VEGF-C overexpression
accelerated wound closure by inducing angiogenesis,
lymphangiogenesis and recruitment of inﬂammatory cells in
diabetic animals9. We recently observed a similar phenomenon
in RhoB / diabetic mice38, suggesting that the impact of
deregulation of angiogenesis and/or lymphangiogenesis by loss of
RhoB could be exacerbated in pathological conditions such as
those occurring in diabetic animals.
Rho family GTPases control many different biological
processes including cell survival, proliferation, adhesion, migra-
tion, gene expression and apoptosis39, and subcellular localization
has been identiﬁed as a critical factor in the ability of these
GTPases to function in different signalling pathways40. To date
there have been only a few reports linking a Rho family GTPase
found in the nucleus to the regulation of gene expression by a
transcription factor. Both RhoA and Rac1 have been reported
to participate in transcriptional complexes involving the
transcription factors Glucocorticoid Receptors and beta-catenin/
TCF4, respectively41,42. A recent study has reported a functional
Net1/RhoA signalling pathway within the nucleus implicated in
the DNA damage response43, and Rac1 signalling has also been
shown to modulate a STAT5/BCL-6 transcriptional switch on
cell-cycle-associated target gene promoters44. The nuclear
localization of these small GTPases may be cell-type-speciﬁc, as
we did not observe RhoA in the nucleus of BVECs and LVECs.
However, our own ﬁndings provide strong evidence for the
participation of nuclear RhoB–GTP in the efﬁcient gene
transcription by VEZF1 through their direct interaction in
endothelial cell nuclei. The association of small GTPases with
transcription factors in the nucleus is a relatively new ﬁnding;
therefore, many outstanding questions remain to be addressed
including the function served by the GTPase in the
transcriptional complex, and the identity of additional proteins
that participate in this transcriptional complex. It has been shown
that the p68RacGAP interacts with VEZF1 and facilitates the
hydrolysis of the GTP form of Rac1 in endothelial cells45. Future
studies will be needed to identify the regulatory partners, for
example, the GAPs and GEFs, present in the RhoB–VEZF1
transcriptional complex, that participate in the RhoB regulation
of VEZF1-mediated gene transcription in BVECs versus LVECs.
Finally, using an in silico approach we identiﬁed a small
molecule inhibitor (VEC6) targeting the VEZF1–DNA binding
interface that was able to recapitulate the effects of the loss of
RhoB in the ischaemic retina. This ﬁnding suggests that the
RhoB–VEZF1 complex represents an interesting new target for
developing novel therapies against numerous pathologies with a
vascular component, for example, diabetic retinopathy. However,
VEC6 was also able to induce LVEC proliferation in vitro similar
to silencing of RhoB, suggesting the possibility of a pro-
lymphangiogenic effect in vivo. Further work using a second
generation of inhibitory molecules more suited for in vivo studies
in adult mice will be needed to address the question of lymphatic
sensitivity and responsiveness.
In conclusion, we propose that RhoB, an immediate early gene
product, located in the nucleus in its GTP form, interacts with the
transcription factor VEZF1 to drive transcription of unique target
gene sets in BVECs versus LVECs, which in turn regulate, at least
in part, the distinct blood and lymphatic endothelial responses to
different pathological stimuli. Additional analysis of this
transcriptional complex will further our understanding of its
differential angiogenic and lymphangiogenic regulatory mechan-
isms and identify new therapeutic strategies for more speciﬁc
intervention of the blood versus lymphatic vasculature. Our
ﬁndings emphasize the broader worth of considering the potential
impact on the lymphatic vascular network of any pro- or anti-
angiogenic therapy. Further understanding the RhoB–VEZF1
pathway may provide crucial information relevant to the
challenge of deﬁning therapies that focus on one vascular bed
versus the other, thus enlarging the impact of our study on the
whole vascular ﬁeld.
Methods
Mice. RhoB / mice, a gift from George Prendergast19, were maintained in both
SV129 and FVB backgrounds. VEZF1þ / mice, a gift from Heidi Stuhlmann22
were maintained in the SV129 background. To study the functional cooperation
between RhoB and VEZF1 in vivo, RhoB / mice in the SV129 background were
crossed with VEZF1þ / mice in the SV129 background. Resulting double
heterozygotes were crossed to obtain all required genotypes in one litter (RhoBþ / ,
VEZF1þ / and RhoBþ /VEZF1þ / ). All studies were conducted in compliance
with the Beth Israel Deaconess Medical Center IACUC guidelines.
Retinopathy of prematurity. Neonatal mice (female and male, eight groups; ﬁve
to six pups per group) were exposed to 75% oxygen beginning on post-natal day
P7, and returned to room air on day P12. Retinas were harvested on day P17, ﬁxed
in 10% formalin for 1 h, and incubated with FITC-Lectin BS-1 (Sigma, St Louis,
MO, USA) in PBS, 0.2% Triton X-100 and 10% Goat serum O/N at 4 C. Retinas
were washed (four to ﬁve times for 1 h) in PBS, ﬂattened and photographed using a
Leica MZFIII microscope and DC200 digital camera. Pups used to evaluate VEZF1
inhibitors were injected i.p. with 30mg per kg per day of test compound from P12
to P17. Their retinas were processed and imaged as above.
Ear acute injury and chronic inﬂammation. Full-thickness wounds were created
in the center of the ears of adult mice (female and male, 6–8 weeks) using a 2-mm
biopsy punch. Seven days post-injury ears were examined by whole-mount staining
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and/or by intravital microscopy to assess both angiogenesis and lymphangiogen-
esis. Chronic inﬂammation was induced by DTH in the ear skin of RhoB null and
wt mice as described previously26. Brieﬂy, adult mice (6–8 weeks) were sensitized
by topical application of a 2% oxazolone (4-ethoxymethylene-2 phenyl-2-
oxazoline-5-one; Sigma) solution in acetone/olive oil (4:1 vol/vol) to the shaved
abdomen (50 ml) and to each paw (5ml). Five days later, ears were challenged by
topical application of 1% oxazolone solution (20 ml). Ear swelling was assessed daily
by ear thickness measurement using a Mitutoyo caliper for 11 days post-challenge.
Lymphangiogenesis was assessed by intravital microscopy.
Ear whole-mount staining. Whole mounts of ears were prepared for confocal
microscopy as previously described8. Ears from adult mice (female and male, 6–8
weeks) were dissected, split into the dorsal and ventral surface and ﬁxed for 3 h in
4% PFA. Tissues were blocked overnight in PBS, 5% goat serum, 0.3% Triton X-100
and then incubated successively O/N in primary antibodies (CD31 (MEC13.3,
553370, BD Pharmingen), and Podoplanin (ab11936, Abcam)) and secondary
antibodies (Jackson) each diluted 1/200 in blocking solution. Samples mounted on
glass slides were observed with a confocal microscope (Zeiss LSM 510 Meta).
Confocal 3D projections were processed by Zeiss LSM Image software. Each 3D
projection image corresponds to a tissue thickness of 100 mm. CD31 signal of 3D
projections was quantiﬁed by using the measure function (% Area) from NIH
ImageJ software, after selection of the wound angiogenic area (white lines).
Ear intravital microlymphangiography. Microlymphangiography was performed
as described27. Ears of anesthetized adult mice (female and male, 6–8 weeks) were
mounted ﬂat on a resin support, held in place by silicone vacuum grease and
viewed in a Leica MZFLIII ﬂuorescent microscope. FITC–dextran (2,000 kDa
lysine-ﬁxable, Invitrogen at 20 mg ml 1 in saline) was injected into the lymphatics
through a 10-mm pre-pulled borosilicate glass micropipette (World Precision
Instruments, Sarasota, FL, USA) attached to a 500ml Hamilton syringe ﬁtted with a
threaded plunger. Using a micromanipulator (WPI), the micropipette was injected
into the dorsal surface of the periphery of the ear in order to engage a lymphatic
lumen. Additional tracer (5–20 ml) was then slowly injected under the control of a
threaded plunger. The progress of the ﬂuorescent tracer through the lymphatic
network was followed in real time by digital image capture (60 framesmin 1)
using a Leica DC350 FX digital camera in conjunction with Image-Pro Plus 6.2
Software. The resultant image stack was combined to produce a movie of tracer
transport. Isolated frames, corresponding to speciﬁc times following tracer
injection, were used to quantify the FITC–dextran tracer signal in each image using
the measure function (% area) from NIH ImageJ software.
Human dermal microvascular endothelial cell isolation. Primary dermal human
microvascular endothelial cells (HMVECs) from human male foreskins (from at
least four individuals) were isolated as previously described46. The Beth Israel
Deaconess Medical Center IRB approved the use of this discarded tissue. No
clinical information or method of identiﬁcation of the donor is provided. Both
BVECs and LVECs were isolated with magnetic Dynabeads pre-associated with
CD31 (Invitrogen). Subsequently, LVECs were separated from BVECs by using
goat anti-mouse Dynabeads associated with Podoplanin antibody (Angiobio). The
purity of these two endothelial cell populations was assessed by Dil-Ac-LDL, CD31
and Prox1 staining (Supplementary Fig. S2a). A total of six different cell isolation
lots were used at passages 4–5 for all in vitro experiments. Each experiment was
performed on at least two different cell isolation lots. HMVECs were grown in pre-
coated plates with collagen I in MCDB131 medium (CellGro) supplemented with
L-Alanyl-L-Glutamine (CellGro, 2mM) and MVGS (Cascade Biologics).
Transfection. siRNA transfection in HMVECs was performed using HMVEC-L
Nucleofector kit (Lonza). Conﬂuent cells were harvested with trypsin-EDTA,
washed in PBS and added to nucleofection solution (100 ml per 1 106 cells).
Programme S-005 was used for transfection. Cells were removed from the cuvette
and plated into a pre-coated six-well culture plate. Final siRNA concentration was
50mM in the plate. RhoB and VEZF1 were silenced by using pre-designed siRNAs
from Ambion (RhoB: siRNA ID# 42060, 41981, 41889, and VEZF1: siRNA ID#
S15222, S15223, S15224). Silencer Select Negative Control #1 siRNA served as
control. VEZF1 overexpression was obtained by transfection of human VEZF1
expression vector (Origene). Luciferase assays were performed using the Dual-
Luciferase Reporter Assay System (Promega).
Adenovirus and mutagenesis. RhoB-Flag adenoviruses were generated using
AdEasy Adenoviral system (Promega). Brieﬂy, human RhoB coding sequence was
ampliﬁed from human primary endothelial cell cDNA and inserted in pShuttle-
IRES-hrGFP-1. Site-directed mutagenesis of RhoB was induced by PCR using
Phusion High-Fidelity DNA polymerase (Fynnzymes) and DpnI digestion. Muta-
genic primers were used to prepare mutants for Constitutive Active (G14V) and
Dominant Negative (T19N) forms of RhoB. All wt and mutant sequences were
checked by DNA sequencing. AdEasy recombinants were generated by electro-
poration of BJ5183 cells containing pAdEasy-1 vector, with PmeI linearized shuttle
vector. Adenoviruses were expanded in 293FT cells and puriﬁed with two CsCl
centrifugations. Puriﬁed adenoviruses were stored in Viral Preservation Media
(Tris–HCl 20mM pH 8, MgCl2 2mM, sucrose 5%) at  80 C. Cells were infected
at an MOI of 50 pfu per cell.
Cell immunostaining. Human dermal endothelial cells, grown in complete med-
ium on coverslips pre-coated with collagen, were collected after 24 h to assess the
proliferation rate with Ki67 antibody (18-0191Z, ZYMED) or at conﬂuence for
Prox1 (20R-PR039, Fitzgerald) and CD31 (555444, BD Pharmingen) immuno-
staining to conﬁrm BVECs versus LVECs population identity. Cells were ﬁxed with
4% paraformaldehyde for 5min, permeabilized and blocked with PBS, 5% goat
serum, 0.1% Triton X-100 for 1 h at room temperature. Primary antibodies were
diluted 1/200 in blocking solution without Triton X-100 and then incubated with
cells at 4 C O/N followed by appropriate secondary antibody (Jackson). Coverslips
were washed and mounted in Dako Fluorescent Mounting Medium containing
DAPI (3 mgml 1). Quantiﬁcation of the proliferation rate with Ki67 antibody was
determined by the analysis of three independent experiments and 10 random ﬁelds
for each experiment.
Sprouting assay. Spheroid production was performed as described47. In 96-well
plates, 400 endothelial cells per well were seeded in 100 ml per well of MVGS media
containing 20% Methylcellulose (Sigma). After 24 h, cell aggregates, named
spheroids, were collected and centrifuged. Three-dimensional cultures of spheroids
were prepared by using the overlay method as previously described48. Spheroids
were resuspended in media containing 2% Growth factor-reduced Matrigel (BD
Biosciences), and seeded on top of the underlay containing a 50:50 mixture
Matrigel and Bovine collagen I (PureCol, 3mgml 1, Inamed Biomaterials). Before
mixing, collagen I was neutralized by addition NaOH (10mM) in 1 PBS and the
pH was brought to 7.5 by using 0.1M HCl. Stimulatory cytokine, (human VEGF-A
(25 ngml 1) or human VEGF-C (100 ngml 1) (RD Systems), respectively for
BVECs and LVECs) was added to the Matrigel/collagen I underlay mixture. After
24 h of stimulation, phase-contrast pictures were taken using a microscope (Nikon
eclipse TE300) equipped with a camera (Leica, DFC 350 FX). Fluorescent images of
GFP-positive cells were obtained by confocal microscopy (Zeiss LSM 510 Meta).
For quantiﬁcation, the cumulative sprout length of 15 randomly selected spheroids
from three independent experiments was reported per data point.
Cell extracts and immunoblot analysis. Cytoplasmic extracts were obtained by
using a cytoplasmic lysis buffer (Triton X-100 0.25%, Tris–HCl 10mM (pH 8),
EDTA 5mM, EGTA 0.5mM and proteases inhibitors (Sigma-P8340)). After cen-
trifugation, the nuclei pellet was resuspended in Urea lysis buffer (Urea 8M, Tris–
HCl 50mM pH 8, EDTA 5mM and proteases inhibitors). Total extracts were
formed by direct cell digestion in urea lysis buffer. Western blot analysis was
performed as described49. Brieﬂy, total extracts were separated on SDS–PAGE and
membranes probed with antibodies recognizing human RhoB (1 in 500) (Cell
Signaling-2098), RhoA (1 in 500) (Bethyl-lab-929), VEZF1 (1 in 500) (Abcam-
ab50970), Tubulin (1 in 1,000) (Calbiochem-CP06), DNA polymerase b (1 in 500)
(Abcam-26343), LYVE-1 (1 in 500) (UpState-07-538), Prox1 (1 in 500) (Fitzgerald-
20R-PR039), CD31 (1 in 500) (BDPharmingen-555444), Podoplanin (1 in 500)
(Angiobio-11-003), VEGFR3 (1 in 500) (SantaCruz-sc-321) and Flag tag (1 in 500)
(Abcam-ab1162).
Chromatin immunoprecipitation. ChIPs were performed using 0.5 106 cells per
IP. Proteins were ﬁrst crosslinked with 1.5mM EGS50, and were then crosslinked to
DNA with 1% formaldehyde. After cytoplasmic fractionation, nuclei were digested
in Complete Digestion Buffer from Nuclear complex Co-IP kit (Active motif).
DNA was sheared by sonication. IP protocol was followed as described by supplier.
Each IP was performed using 6 mg of antibodies against human VEZF1 (Abcam-
ab85414), Flag tag (Sigma-F1804) and human Polymerase II (Covance-MMS-
126R) and compared with IgG controls. DNA was puriﬁed as described in (ref. 51).
Brieﬂy, formaldehyde crosslinks were reversed at 67 C for overnight. Samples were
incubated with RNaseA and puriﬁed using Qiagen Qiaquick PCR puriﬁcation kit.
DNA enrichment was analysed by real-time PCR.
GTP pull-down assay. RhoB activity was assessed by measuring the amount of
GTP-bound form of RhoB using the small GTPase activation assay (STA-403)
from Cell Biolabs. In all, 5 106 cells were used for each pull-down reaction
performed with Rhoketin RBD Agarose beads, as described by manufacturer. The
proteins were revealed by immunoblot analysis using antibodies recognizing
human RhoB and Flag tag.
Analysis of gene expression. Total RNAs from two independent cell isolation
lots, each from at least four separate individuals, were isolated using RNeasy
Kit and treated by DNase I during extraction steps (Qiagen). cDNAs were prepared
from 0.5 mg total RNA using random hexaprimers as templates and SuperScript III
(Invitrogen). Quantitative real-time RT–PCR (QRT–PCR) was carried out
on an AbiPrism 7500 system using SYBR Green. The primer sequences are
available in Supplementary Table S2. For Affymetrix GeneChip probe array, 1 mg
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total RNA of one cell isolation lot from at least four separate individuals was used
to synthetize cRNA, which was hybridized to Affymetrix HT Human U133A
GeneChips. Fold change of gene expression and GO analysis were established using
the dChip software52. Present probe sets with a differential expression ofZ1.5-fold
and Po0.05 were taken into account.
Proximity ligation assay. Cells grown on collagen-coated 10-cm culture plates
were co-transfected with 0.5 mg each of DNA encoding Flag-VEZF1 (OriGene) and
V5-RhoB (HMVEC-L kit from Lonza). Cells were plated in collagen-coated eight-
well slide chambers and incubated for 24 h at 37 C to allow protein expression,
then ﬁxed, permeabilized and incubated with primary antibodies (mouse mono-
clonal anti-Flag (Sigma-F1804) plus rabbit polyclonal anti-V5 (Abcam-ab15828),
all diluted 1:400) for 1 h. Cells were washed with provided blocking buffer and then
incubated for 1 h with anti-mouse (þ ) and anti-rabbit ( ) proximity ligation
secondary antibodies, diluted 1:5, at 37 C (PLA, DuolinkII system from Olink
Bioscience). DNA ampliﬁcation and ﬂuorescent probes hybridization were per-
formed as per instructions. Coverslips were mounted on slides and imaged by A1
Nikon confocal imaging system.
Statistical analysis. Results were presented as mean±s.e.m. Statistical sig-
niﬁcance of all data were analysed using the unpaired two-tailed Student’s t-test in
the Microsoft Ofﬁce Excel 2003 software. P-values o0.05 were considered to be
statistically signiﬁcant.
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